We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00530101
Recruitment Status : Completed
First Posted : September 17, 2007
Last Update Posted : June 4, 2008
Sponsor:
Collaborator:
Information provided by:

Study Description
Brief Summary:

The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans.

This research study is expected to enroll approximately 10 subjects over 12 months at the University of Miami / Miller School of Medicine.


Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Doxorubicin Phase 1

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity
Study Start Date : July 2004
Primary Completion Date : March 2008
Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Intervention Details:
    Drug: Doxorubicin

    This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:

    Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2

    Other Name: 1177-04-806

Outcome Measures

Primary Outcome Measures :
  1. The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans. [ Time Frame: Over a period of 12 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must have breast cancer and undergoing radiation treatment with a likelihood of developing cardiotoxicity.

Exclusion Criteria:

  • Healthy subjects
  • Males
  • Subjects under the age of 18
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00530101


Locations
United States, Florida
University of Miami Dept of Hematology/Oncology
Miami, Florida, United States, 33136
University of Miami Dept of Radiology
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
Mallinckrodt
Investigators
Principal Investigator: Joel Fishman, MD University of Miami
More Information

Responsible Party: Dr. Joel Fishman, University of Miami
ClinicalTrials.gov Identifier: NCT00530101     History of Changes
Other Study ID Numbers: 1177-04-806
20043031 and 20050866
First Posted: September 17, 2007    Key Record Dates
Last Update Posted: June 4, 2008
Last Verified: June 2008

Additional relevant MeSH terms:
Cardiotoxicity
Pathologic Processes
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Radiation Injuries
Wounds and Injuries
Doxorubicin
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action